Related Experiment Video
Updated: Feb 15, 2026

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
Published on: May 2, 2013
Immunotherapy using regulatory T cells in cancer suggests more flavors of hypersensitivity type IV
Nafiseh Pakravan1, Zuhair Mohammad Hassan2
1Division of Immunology, Medical School, Alborz University of Medical Sciences, Karaj, Iran.
Abstract:
Regulatory T cells (Tregs) profoundly affect tumor microenvironment and exert dominant suppression over antitumor immunity in response to self-antigen expressed by tumor. Immunotherapy targeting Tregs lead to a significant improvement in antitumor immunity. Intradermal injection of tumor antigen results in negative delayed-type hypersensitivity (DTH) type IV. However, anti-Tregs treatment/use of adjuvant along with tumor antigens turns DTH to positive. Considering Tregs as the earliest tumor sensor/responders, tumor can be regarded as Treg-mediated type IV hypersensitivity and negative DTH to tumor antigen is due to anti-inflammatory action of Tregs to tumor antigens at the injection site. Such a view would help us in basic and clinical situations to testify a candidate vaccine via dermal administration and evaluation of Treg proportion at injection site.
Related Concept Videos
Hypersensitivities
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
Hypersensitivity Reactions: Delayed Hypersensitivity Reactions
Cis-regulatory Sequences
Cis-regulatory Sequences
Type IV Collagen of Basal Lamina
A type IV collagen molecule has six alpha chains which can...
Tumor Immunotherapy

